APR 25, 2017 10:00 AM PDT

WEBINAR: Discover Potentially Predictive Immuno-Oncology Biomarkers using Next-Gen Sequencing

Speakers

Abstract

DATE: April 25, 2017
TIME: 10:00am PT, 1:00pm ET

Immunotherapy has emerged as one of the most promising options for the future treatment of a growing number of cancers and is touted to be the next revolution in our fight against this complex disease. One of the most effective modalities of treatment, thus far, has been in the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors.

Current biomarkers and immunohistochemistry (IHC) assays are not accurate predictors of which individuals are most likely to respond or benefit from immunotherapeutic agents, thus prompting the need to identify better biomarkers that can guide therapy selection in the future. 

Next-generation sequencing (NGS) offers clinical researchers a cost-efficient and rapid way of analyzing multiple targets simultaneously from as little as 10ng of total RNA isolated from formalin-fixed, paraffin-embedded (FFPE) samples.  

In this webinar, our speakers will show how Thermo Fisher Scientific’s Oncomine Immune Response Research Assay enables the interrogation of gene targets that are critical for research into immune response.
 
Topics to be covered:

  • Fiona Hyland will describe how the content for a new gene expression NGS-based assay was carefully selected and will compare its performance against other assay(s) available on the market.
  • Dr. Carl Morrison will describe a verification study for establishing the performance of the new Oncomine Immune Response Research Assay in a clinical research lab.

Key learning objectives for attendees:

  • How to improve immuno-oncology biomarker discovery using NGS
  • Benefits of applying a targeted gene-expression based approach for studying the tumor microenvironment
  • How to implement the Oncomine Immune Response Research Assay in a clinical research lab 

Who should attend:

  • Scientists involved in biomarker discovery and drug development 
  • Contract Research Organizations focused on oncology services
  • Immunology and oncology translational/clinical research laboratories interested in adopting NGS


For Research Use Only. Not for use in diagnostic procedures.


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
MAR 23, 2022 11:00 AM PDT
MAR 23, 2022 11:00 AM PDT
Date: March 23, 2021 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEDT) In this presentation, Dr. Middleton will review the development and deployment of large-scale saliva-based COVID-19 test...
MAR 30, 2022 6:00 AM PDT
MAR 30, 2022 6:00 AM PDT
Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic...
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
AUG 16, 2022 11:00 AM PDT
AUG 16, 2022 11:00 AM PDT
Date: August 16, 2022 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEST) Understanding genomic variation in the context of cancer is paramount to identifying disease drivers and informing pers...
APR 25, 2017 10:00 AM PDT

WEBINAR: Discover Potentially Predictive Immuno-Oncology Biomarkers using Next-Gen Sequencing



Show Resources
Loading Comments...
Show Resources